2 not developing pregnancy - cry of the help

[_]

1 aja the stood pregnancy in 1995 on term of 13 weeks (according to doctors - 8 weeks) .sejchas again stood pregnancy in the same term. This pregnancy planned with the doctor, it was surveyed on what only probably, including on an infection. Infections it was revealed not. The doctor has given OK to pregnancy, preliminary having prepared me - +.

There were 3 cleanings (2 +1 a polyp endometrija zhelezisto fibrous) .chto still to check already and I do not know, I in despair, me 31 year, was not present children. Help or assist what to do or make.

In advance thanks.

[AlenaL]

Dear YBLOKO!

I do not know, whether it will help or assist you, but sometimes a fetal stopping of a fetation (as well as set of other problems at pregnancy) are connected with presence at the patient of predilection to a clottage (thrombophilia). There is a plenty of explanations of it or this, and not smaller quantity or amount of the reasons on which not always there is an opportunity to be surveyed even in Moscow. The short of problems consists in a microthrombosing of a placenta that conducts to disturbance of blood supply of a fetus, therefore purpose or appointment of direct anticoagulants for all period of pregnancy (the low-molecular heparin is better) allows to increase conservation of pregnancy from a comment of 19-20 % up to 70-75 %. At presence antifosfolipidnyh antibodies to NMG Aspirinum in small doses is added, at presence gomotsisteinemii - Acidum folicum. If you will again be decided to plan pregnancy with vrachem I can send you English originals of clauses or articles on a subject for more detailed acquaintance.

And 31 year it not critical age: similar singer the Madonna suffered similar problems (a habitual abortion), but with the advent of new knowledge to the extremity or end 90 could give birth and not to one in the age of under 40.

Something on a subject

Hypertens Pregnancy 2001; 20 (1):35-44

Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias.

Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, Eldor A.

The Department of Obstetrics and Gynecology, Lis Maternity Hospital, Tel-Aviv University, Tel-Aviv, Israel. tmcobgyn@tasmc.health.gov.il

OBJECTIVE: To evaluate the benefit of combined low-molecular-weight (LMW) heparin and aspirin for prophylaxis in women carriers of thrombophilia who had previously suffered from severe obstetric complications. METHODS: The 33 studied women had an earlier pregnancy complicated by severe preeclampsia, abruptio placentae, intrauterine growth retardation, or intrauterine fetal death. All were subsequently diagnosed as carrying inherited thrombophilias. In their subsequent pregnancy, prophylactic therapy consisting of LMW heparin 40 mg/day (Enoxaparin, Rhone-Poulenc-Rorer, France) and aspirin was administered. Patients who were found to be homozygotes for the methylenetetrahydrofolate reductase mutation also received folic acid supplementation throughout their pregnancy. RESULTS: Low-molecular-weight heparin was well tolerated and none of the women or the newborns developed any hemorrhagic complications. Only three (9.1 %) of the women developed pregnancy complications. The mean gestational age and the mean birth weight at delivery in the previously complicated pregnancies were 32.1 +/-5.0 weeks and 1175 +/-590 g, respectively, compared to 37.6 +/-2.3 weeks and 2719 +/-526 g, respectively, in the treated pregnancies (p *lt; 0.001). CONCLUSIONS: This uncontrolled trial suggests that patients with obstetric complications and an inherited thrombophilia may benefit from treatment with combined LMW heparin and aspirin in subsequent pregnancies. However, this needs to be verified by controlled trials before considering clinical application.



[Abstr.2765, Blood 2002] Efficacy and Safety of Two Doses of Enoxaparin in Pregnant Women with Thrombophilia and Recurrent Pregnancy Loss. The LIVE-ENOX Study.

Benjamin Brenner, for the LIVE-ENOX Investigators. Thrombosis and Hemostasis Unit, Rambam Medical Center, Haifa, Israel

Objectives: Thrombophilia in women is associated with pregnancy loss. Enoxaparin may improve gestational outcome in women with thrombophilia and a history of pregnancy loss. However, the optimal dose of enoxaparin in these patients has not been determined. The aims of this study are to evaluate the efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and a history of pregnancy loss. Methods: LIVE-ENOX is a prospective, open-label randomized multicenter trial comparing subcutaneous enoxaparin 40 mg/day with 80 mg/day (40 mg b.i.d.) in women with thrombophilia and previous pregnancy loss (3 losses in first trimester, 2 losses in second trimester or 1 loss in third trimester). Women were included in this study at 5-10 weeks of gestation and treatment with enoxaparin is given throughout gestation and the post-partum period. Women with antiphospholipid syndrome also receive aspirin 75 mg/day. Patients are followed-up at monthly intervals to check maternal safety, fetal growth and development, and anti-Xa levels; and at bimonthly intervals for placental perfusion by Doppler velocimetry studies. The primary outcome is delivery of a live healthy infant. The secondary outcome is prevention of gestational vascular complications. The study includes 180 evaluable gestations, 90 in each treatment arm and is being conducted in 12 centers in Israel. Results: The first patient was enrolled in March 2000, the last in March 2002. The study groups are similar regarding type of thrombophilia, the number of previous pregnancies and the timing of previous pregnancy losses.

results (40 mg/day/Enoxaparin/80 mg/day):

Mean neonatal weight of babies (g): 2,973702 / 2,957608

Pre-eclampsia (%): 2 / 4

Placental abruption (%): 6 / 2

No thrombotic episodes or major bleeding episodes were recorded. None of the patients developed heparin-induced thrombocytopenia.